Vistagen Therapeutics Inc (VTGN)
4.45
-0.21
(-4.51%)
USD |
NASDAQ |
May 08, 16:00
4.47
+0.02
(+0.45%)
After-Hours: 20:00
Vistagen Therapeutics Revenue (Quarterly): 0.4114M for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 0.4114M |
| September 30, 2023 | 0.2777M |
| June 30, 2023 | 0.1776M |
| March 31, 2023 | 0.1756M |
| December 31, 2022 | 0.1796M |
| September 30, 2022 | -0.8925M |
| June 30, 2022 | 0.3101M |
| March 31, 2022 | 0.0389M |
| December 31, 2021 | 0.3579M |
| September 30, 2021 | 0.358M |
| June 30, 2021 | 0.3541M |
| March 31, 2021 | 0.4419M |
| December 31, 2020 | 0.3136M |
| September 30, 2020 | 0.334M |
| June 30, 2020 | |
| March 31, 2020 | |
| December 31, 2019 | |
| September 30, 2019 | |
| June 30, 2019 | |
| March 31, 2019 | |
| December 31, 2018 | |
| September 30, 2018 | |
| June 30, 2018 | |
| March 31, 2018 | |
| December 31, 2017 |
| Date | Value |
|---|---|
| September 30, 2017 | |
| June 30, 2017 | |
| March 31, 2017 | |
| December 31, 2016 | 1.25M |
| September 30, 2016 | |
| June 30, 2016 | |
| March 31, 2016 | |
| December 31, 2015 | |
| September 30, 2015 | |
| June 30, 2015 | |
| March 31, 2015 | |
| December 31, 2014 | |
| September 30, 2014 | |
| June 30, 2014 | |
| March 31, 2014 | |
| December 31, 2013 | |
| September 30, 2013 | |
| June 30, 2013 | |
| March 31, 2013 | |
| December 31, 2012 | |
| September 30, 2012 | |
| June 30, 2012 | 0.2004M |
| March 31, 2012 | 0.4689M |
| December 31, 2011 | 0.0024M |
| September 30, 2011 | 0.3163M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
-0.8925M
Minimum
Sep 2022
0.4419M
Maximum
Mar 2021
0.2027M
Average
0.3118M
Median
Revenue (Quarterly) Benchmarks
| Ardelyx Inc | 46.02M |
| Axsome Therapeutics Inc | 75.00M |
| Vir Biotechnology Inc | 51.20M |
| Immuneering Corp | -- |
| NovaBay Pharmaceuticals Inc | 3.727M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -6.350M |
| Total Expenses (Quarterly) | 8.296M |
| EPS Diluted (Quarterly) | -0.22 |
| Enterprise Value | -6.297M |
| Profit Margin (Quarterly) | -1.54K% |
| Earnings Yield | -78.86% |
| Normalized Earnings Yield | -78.86 |